Steady India business uptick for Lupin

VISUFARMA ACQUISITION TO BOOST DRUGMAKER’S PROSPECTS IN EUROPE

- 

LUPIN REPORTED A stronger-thanexpected Q3FY26 performance, driven primarily by robust traction in the US market, where revenue rose 46.8% year-on-year (yo-y) to $350 million.

Growth in the region was led by key products including Tolvaptan, Mirabegron and Spiriva, offsetting the seasonality of some other products. While competitive entry in Tolvaptan remains a near-term risk, management indicated that competitive pressures for Mirabegron and Spiriva are likely to emerge later, supporting near-term earnings visibility.